Apogee Therapeutics (APGE) Other financing activities (2023 - 2026)

Apogee Therapeutics (APGE) has 4 years of Other financing activities data on file, last reported at $17.2 million in Q1 2026.

• Other financing activities for Q1 2026 came in at $17.2 million, up 54.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $52.3 million (up 72.79% YoY), and the FY2025 annual result was $46.3 million, up 98.34% from the prior year.
• Other financing activities climbed to $17.2 million in Q1 2026 per APGE's latest filing, from $11.9 million in the prior quarter.
• Over five years, Other financing activities peaked at $177.5 million in Q3 2023 and troughed at -$173.8 million in Q4 2023.
• A 4-year average of $7.1 million and a median of $7.6 million in 2024 frame the typical range for Other financing activities.
• On a YoY basis, Other financing activities climbed as much as 411.95% in 2024 and fell as far as 96.71% in 2024.
• A 4-year view of Other financing activities shows it stood at -$173.8 million in 2023, then jumped by 104.38% to $7.6 million in 2024, then soared by 56.79% to $11.9 million in 2025, then soared by 43.8% to $17.2 million in 2026.
• Business Quant data shows APGE's Other financing activities at $17.2 million in Q1 2026, $11.9 million in Q4 2025, and $11.9 million in Q3 2025.